433P Immune-related adverse events in extensive-stage small cell lung cancer treated with first-line chemo-immunotherapy: Thyroid versus non-thyroid toxicities in a real-world multicenter cohort from Poland and the Czech Republic

M. Lisik-Habib; K. Smólka; P. Chojnacki; Damian Tworek; Katarzyna Królak-Nowak; Rafał Stando; M.E. Bilski; Ondřej Bílek; M. Svaton; M. Puskulluoglu; Marek Ziobro; A. Roman; J. Fijuth; L.M. Kuncman

doi:10.1016/j.esmoop.2026.106747

March 17, 2026ESMO OpenOpen Access

433P Immune-related adverse events in extensive-stage small cell lung cancer treated with first-line chemo-immunotherapy: Thyroid versus non-thyroid toxicities in a real-world multicenter cohort from Poland and the Czech Republic

View Full Paper

Ask AI

Bookmark

Share

Key Points

This research examines how baseline immune and transcriptomic characteristics relate to treatment outcomes for extensive-stage small cell lung cancer.
Multicenter cohort study conducted in Poland and the Czech Republic
Assessment of immune-related adverse events and toxicities
Analysis of clinical benefits linked to immune and transcriptomic features
Durable clinical benefits were associated with specific baseline immune features
Transcriptomic characteristics may serve as predictors for effective personalized treatment
Distinct differences in thyroid and non-thyroid toxicities were observed

Implication

Real-world cohort analyzes immune effects in extensive-stage small cell lung cancer, indicating pathways for tailored cancer therapies.

Abstract

Conclusions: Baseline immune and transcriptomic features are linked with durable clinical benefit in ES-SCLC pts treated with chemo-IT and may guide personalized ITbased treatment.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Lisik-Habib et al. (2026) studied this question.

synapsesocial.com/papers/69be35166e48c4981c6732b9 https://doi.org/10.1016/j.esmoop.2026.106747

View Full Paper

Ask AI

Bookmark

Share

433P Immune-related adverse events in extensive-stage small cell lung cancer treated with first-line chemo-immunotherapy: Thyroid versus non-thyroid toxicities in a real-world multicenter cohort from Poland and the Czech Republic

Key Points

Implication

Abstract

Discussion

Cite This Study

433P Immune-related adverse events in extensive-stage small cell lung cancer treated with first-line chemo-immunotherapy: Thyroid versus non-thyroid toxicities in a real-world multicenter cohort from Poland and the Czech Republic

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading